Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress

SOUTH SAN FRANCISCO, CA, June 26, 2026 – Star Therapeutics, a late clinical-stage biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced an upcoming oral presentation of complete safety and efficacy data...